October 21, 2019December 30, 2019

Trastuzumab Deruxtecan Gets FDA Priority Review for Metastatic HER2-Positive Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has granted priority review to the application seeking trastuzumab deruxtecan‘s (DS-8201) approval for the treatment of metastatic HER2-positive breast cancer. The agency has ... Read more

May 15, 2019

Experimental Antibody Therapy Leads to Significant Responses in HER2-positive Breast Cancer, Phase 2 Trial Shows

News

Trastuzumab deruxtecan (DS-8201), an investigational antibody-drug conjugate developed by AstraZeneca with Daiicho Sankyo, led to clinically meaningful responses in patients with advanced HER2-positive breast cancer, a Phase 2 clinical trial ... Read more